Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 5/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308355 | 0.80 | CA2 (0.42) | EGFRSRCCA2SHBGAPP | |
| SCHEMBL308343 | 0.80 | SHBG (0.67) | SHBGAPPUSP2RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL22412949 | 0.79 | CA2 (0.41) | EGFRSRCCA2SHBGAPP | |
| SCHEMBL223274 | 0.77 | PTPRC (0.59) | CA2L3MBTL1NCOA1NCOA3RAB9A | |
| SCHEMBL29791652 | 0.77 | PTPRC (0.59) | CA2L3MBTL1NCOA1NCOA3RAB9A | |
| SCHEMBL22426083 | 0.76 | CA2 (0.40) | EGFRSRCCA2SHBGAPP | |
| SCHEMBL28348664 | 0.76 | PTPRC (0.58) | CA2L3MBTL1NCOA1NCOA3RAB9A | |
| SCHEMBL4143009 | 0.75 | MAOB (0.62) | EGFRSRCCA2SHBGAPP | |
| SCHEMBL5656896 | 0.74 | KDM4E (0.49) | EGFRCA2SHBGAPPRAB9A | |
| SCHEMBL20208913 | 0.73 | ALOX5 (0.57) | CA2APPMITFNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962992-B2 | Crown ether derivatives for use in enhancing transfer of indicators into viabile cells | MOLECULLAR PROBES, INC. (US) | 2005-11-08 | — | — | US | claimed |
| US-20020164616-A1 | Crown ether derivatives | MOLECULAR PROBES, INC. (US) | 2002-11-07 | — | — | US | claimed |
| US-12487180-B2 | Device and methods for quantifying analytes introduction | Life Technologies Corporation (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4633458-A1 | SYSTEMS AND METHODS FOR ANALYTE DETECTION | Adaptyx Biosciences, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4565237-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA | Chimerix, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119997956-A | Pharmaceutical composition and use thereof for treating glioma | 奇默里克斯公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250120620-A1 | SYSTEMS AND METHODS FOR ANALYTE DETECTION | Adaptyx Biosciences, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-4524567-A2 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | Oncoceutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240366613-A1 | IMPRIDONES FOR GLIOMAS | ONCOCEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-12109019-B2 | Systems and methods for analyte detection | Adaptyx Biosciences, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-12102639-B2 | Imipridones for gliomas | ONCOCEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2003030817-A2 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | MOLECULAR PROBES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20020164616-A1 | Crown ether derivatives | MOLECULAR PROBES, INC. (US) | 2002-11-07 | — | — | US | disclosed |
| US-6229055-B1 | SYNTHESIS OF FLUORINATED RESORCINOL WHICH IS USEFUL IN THE PREPARATION OF FLUORINATED FLUORESCEIN AND RHODOL DYES SUITABLE FOR USE AS TRACERS, LABELS, OR INTERMEDIATES | MOLECULAR PROBES, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6162931-A | Fluorinated xanthene derivatives | MOLECULAR PROBES, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-6130101-A | FLUORESCENT PROBES FOR USE IN BIOLOGICAL SAMPLES | MOLECULAR PROBES, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0396642-B1 | ENZYME CONTROLLED RELEASE SYSTEM | POLAROID CORP (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5112739-A | Quinone-methide elimination | POLAROID CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0396642-A1 | ENZYME CONTROLLED RELEASE SYSTEM. | POLAROID CORP (US) | 1990-11-14 | — | — | EP | disclosed |
| WO-1990001558-A1 | ENZYME CONTROLLED RELEASE SYSTEM | POLAROID CORPORATION (US) | 1990-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102639-B2 | Imipridones for gliomas | HRH3, HTR2A, HTR4 | EGFR 1062/4885SRC 4270/4885CA2 4389/4885 |
| US-20020164616-A1 | Crown ether derivatives | CD2, SLC40A1, NCOA1 | EGFR 1677/4885SRC 2248/4885CA2 208/4885 |
| US-20240366613-A1 | IMPRIDONES FOR GLIOMAS | GRM3, HRH3, HTR2A | EGFR 1234/4885SRC 3644/4885CA2 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.